A

Amgen

Makes biotech medicines for serious illnesses

Japan Regulatory Strategy Manager

Full-TimeUpdated on 10/21/2026
No salary listed
Expert
Bachelor's
Tokyo, Japan
Hybrid
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A bachelor's degree and at least 10 years of directly related experience, including at least 5 years of Regulatory Affairs experience.
  • In-depth regulatory experience.
  • Knowledge of Japanese legislation and regulations relating to medicinal products.
  • Knowledge of drug development and scientific/technical excellence.
  • Ability to work in matrix environments, including cross-functional and global teams.
  • Ability to work under minimal direction with a medium degree of autonomy.
  • Analytical skills to evaluate and interpret complex situations and problems.
  • Ability to anticipate and prevent potential problems.
  • Ability to independently develop thorough, practical solutions consistent with functional objectives.
  • Understanding of regulatory activities and how they affect projects and processes.
  • Ability to understand and communicate scientific and clinical information.
  • Organizational, communication, and time-management skills to manage multiple assignments and processes.
  • Native-level Japanese.
  • Proficiency with Microsoft Outlook, Word, Excel, PowerPoint, and communication tools.
Responsibilities
  • Develop and execute regulatory strategies and plans, provide strategic regulatory expertise for drug development, interface with regulatory authorities, align with cross-functional partners, integrate regulatory work into commercialization, and continuously improve business processes.
  • Manage product-specific regulatory activities for multiple assigned Amgen products.
  • Work closely with the Global Regulatory Lead to integrate Japan regulatory strategy into global regulatory strategy.
  • Develop and implement Japan regulatory strategy aligned with global regulatory strategy.
  • Provide guidance on local mechanisms to accelerate or optimize product development and regulatory approvals.
  • Influence global regulatory strategy development to align Japan development.
  • Identify opportunities to accelerate development or approval and increase program value to serve more patients.
  • Contribute to filing plans by advising and discussing with local and global cross-functional teams.
  • Lead preparation of regulatory submissions, including New Drug Applications, PMDA consultation briefing documents, Clinical Trial Notifications, and Orphan Drug Applications in Japan, according to the filing plan.
  • Ensure regulatory submissions are timely and meet corporate and local regulatory requirements.
  • Collaborate with Clinical Study Operations teams to support local clinical-study planning and execution in accordance with national legal and regulatory requirements.
  • Ensure local labels are developed and maintained in line with local regulations and company standards and procedures.
  • Develop regulatory strategies and mitigate regulatory risks across Regulatory Affairs Japan and Amgen.
  • Lead process standardization and simplification to improve regulatory-process efficiency.
  • Increase the visibility of Regulatory Affairs Japan and provide support to the Japan Regulatory Strategy Group Head.
  • Work cross-functionally with teams involved in New Drug Applications, PMDA consultations, and Clinical Trial Notifications.
  • Communicate clearly and promptly with business stakeholders.
  • Provide subject-matter expertise for local, regional, and global initiatives.
  • Act as the primary interface with Japan's Ministry of Health, Labour and Welfare and Pharmaceuticals and Medical Devices Agency for product approval and clinical development.
  • Lead and contribute to health-authority interaction strategy and attend health-authority meetings.
  • Develop and maintain relationships with Japanese health authorities to facilitate drug approvals.
  • Engage with local trade associations to shape the external environment, monitor national legislation, and provide timely feedback to global and local colleagues.
  • Maintain regulatory compliance for documents submitted to health authorities and post-approval commitments.
  • Support monitoring, auditing, and self-assessment activities under the compliance framework.
  • Contribute to the development and implementation of country-specific compliance procedures and working practices.
Desired Qualifications
  • An advanced degree.
  • A TOEIC score of at least 860.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.

Yahoo Finance
Oct 8th, 2026
Amgen invests $2.6B in manufacturing for MariTide obesity drug ahead of Phase III results

Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.

Yahoo Finance
Sep 29th, 2026
Amgen lifts dividend 6%, but eroding Prolia and Enbrel sales shift focus to MariTide Phase 3

Amgen raised its quarterly dividend 6% to $2.52 per share, marking its 14th consecutive annual increase since starting payouts in 2011. The biotech now pays $10.08 annually, yielding 2.36% at current share prices of $418.13. The dividend appears well covered. Amgen generated $8.1 billion in free cash flow in 2025 against $5.1 billion in dividend payments. Second quarter 2026 free cash flow reached $3.5 billion whilst dividends consumed $1.4 billion. However, biosimilar competition is eroding legacy revenue. Prolia and XGEVA sales dropped 33% whilst Enbrel fell 37%. The company carries $57 billion in debt. Future dividend growth may hinge on Phase 3 results for MariTide, Amgen's obesity candidate. The company follows a steady raise pattern similar to Johnson & Johnson, contrasting with Pfizer's post-COVID payout struggles.

Yahoo Finance
Sep 26th, 2026
Vertex and Amgen deliver promising pipeline updates as both outperform market

Vertex Pharmaceuticals reported strong second-quarter results, with revenue rising 12% year-over-year to $3.33 billion and earnings per share climbing 8% to $4.31. The company posted positive Phase 2b results for inaxaplin, an experimental treatment for APOL1-mediated kidney disease, showing it reduced proteinuria in patients with modest protein levels and those with type 2 diabetes. Vertex expects approval for povetacicept, a treatment for IgA nephropathy, by November. The company continues diversifying beyond its core cystic fibrosis franchise, which provides predictable revenue as patients require lifelong treatment. Meanwhile, Amgen has also outperformed the broader market this year, though specific recent developments were not detailed in the source material.